PASCAL

Edwards Lifesciences Reports First Quarter Results

Retrieved on: 
Thursday, April 25, 2024
Managed Care, Biotechnology, Health, Cardiology, Acumen, Mortality, FDA, Critical care, Investment, Pulmonary artery catheter, Research, Trial of the century, Aortic stenosis, Growth, Ultra, U.S. FDA, ICU, TAVR, Patient, PROGRESS, EPS, Hospital, PASCAL, Quality of life, M3, Heart failure, Pharmaceutical industry

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended March 31, 2024.

Key Points: 
  • Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended March 31, 2024.
  • Surgical Structural Heart sales for the quarter were $266 million, which grew 7%, or 8% on a constant currency basis.
  • For the quarter, the adjusted gross profit margin was 76.0%, compared to 77.5% in the same period last year.
  • For the second quarter of 2024, the company projects total sales to be between $1.62 and $1.70 billion, and adjusted EPS of $0.67 to $0.71.

Edwards Lifesciences Reports Fourth Quarter Results

Retrieved on: 
Tuesday, February 6, 2024
Health, Medical Devices, Biometrics, Health Technology, General Health, Cardiology, Biotechnology, Acumen, EPS, SMART Recovery, Critical care, Growth, Mortality, PASCAL, Science, Aortic stenosis, PROGRESS, TAVR, Clinical trial, Research, Patient, FDA, Investment, M3, CE marking, Heart failure, Hypotension, Share repurchase, Completeness, U.S. FDA, Pharmaceutical industry

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended December 31, 2023.

Key Points: 
  • Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended December 31, 2023.
  • In the fourth quarter, Edwards remained focused on its key value drivers to unlock the significant long-term opportunity for patients: a portfolio of differentiated therapies; positive clinical trial results to support approvals and adoption; and favorable real-world clinical outcomes.
  • Research and development expenses in the fourth quarter grew 16 percent over the prior year to $270 million, or 17.6 percent of sales.
  • During the fourth quarter, the company repurchased $444 million of stock through a combination of a pre-established trading plan and accelerated share repurchase programs.

Edwards Lifesciences Outlines Growth Strategy at Annual Investor Conference

Retrieved on: 
Thursday, December 7, 2023
General Health, Health, Cardiology, TAVR, Corporation, NYSE, Tricuspid valve, Investment, Surgery, Percutaneous aortic valve replacement, Patient, CE marking, PASCAL, PROGRESS, Conference, CLASP, Aortic stenosis, Growth, Development, TCT, Edwards Lifesciences, Critical care, Pharmaceutical industry, Nursing, Pet industry, Management

Edwards Lifesciences Corporation (NYSE: EW) will discuss the company’s sharpened focus and strategy for longer-term growth, provide an update on its technology pipeline and share financial guidance1 today during its annual investor conference.

Key Points: 
  • Edwards Lifesciences Corporation (NYSE: EW) will discuss the company’s sharpened focus and strategy for longer-term growth, provide an update on its technology pipeline and share financial guidance1 today during its annual investor conference.
  • Continued progress across these areas will result in more patients diagnosed and treated with Edwards’ repair and replacement technologies, and a significant long-term growth opportunity.
  • Also in 2024, Edwards expects to accelerate its surgical mitral leadership with the global commercialization of its MITRIS RESILIA valve.
  • During the conference, Edwards’ management will reaffirm the company’s 2023 financial guidance and provide guidance for 2024.

Iridex Announces Strategic Review to Unlock Shareholder Value

Retrieved on: 
Tuesday, August 29, 2023
Retina, Glaucoma, IRIX, Disclosure, PASCAL, COVID, History, Silicon, Patient, Physician, Engineering, Ophthalmology, Growth, OUS, Management, Pharmaceutical industry

MOUNTAIN VIEW, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX) announced today that its Board of Directors is undertaking, in consultation with its financial and legal advisors, a review and evaluation of strategic alternatives that may be available to the Company to unlock shareholder value.

Key Points: 
  • MOUNTAIN VIEW, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX) announced today that its Board of Directors is undertaking, in consultation with its financial and legal advisors, a review and evaluation of strategic alternatives that may be available to the Company to unlock shareholder value.
  • Iridex has engaged Piper Sandler to act as financial advisor in connection with the strategic review process.
  • “Iridex is a worldwide leader in laser-based medical systems for the ophthalmology market, with proven platforms, systems and consumable technologies for the treatment of glaucoma and retinal diseases,” said David Bruce, President and CEO.
  • Iridex has not set a timetable for completion of the strategic process and does not intend to disclose further developments unless and until it is determined that further disclosure is appropriate or necessary.

Iridex Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Thursday, March 9, 2023
PASCAL, Glaucoma, Retina, IRIX, FDA, Growth, Forgiveness, Investment, PPP, Sale, Average cost, Cryptocurrency, Pharmaceutical industry, Fine chemical, Microscope, Video game, Film industry

MOUNTAIN VIEW, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today reported financial results for the fourth quarter and year ended December 31, 2022 and issued 2023 financial guidance.

Key Points: 
  • MOUNTAIN VIEW, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today reported financial results for the fourth quarter and year ended December 31, 2022 and issued 2023 financial guidance.
  • “In 2022 we continued to reestablish the foundation for customer adoption and market penetration with our Cyclo G6 glaucoma treatment platform.
  • Total product revenue from the Cyclo G6 glaucoma product group was $4.2 million, 9% higher than the fourth quarter of 2021 driven by higher Cyclo G6 probe sales.
  • Operating expenses for the fourth quarter of 2022 decreased 4% to $8.1 million compared to $8.4 million in the same period of the prior year.

EDWARDS ANNOUNCES SIX-MONTH DATA CONFIRMING TEER AS SAFE AND EFFECTIVE FOR DMR IN FIRST HEAD-TO-HEAD TRIAL

Retrieved on: 
Saturday, September 17, 2022
Linda, Safety, Edwards Lifesciences, Quality of life, Alfieri, Critical care, U.S. Securities and Exchange Commission, Ventricular remodeling, MitraClip, Significance, CLASP, Drug Quality and Security Act, Annual report, DMR, View, YouTube, PASCAL, NYSE, MD, Quality, CE marking, News, Forward-looking statement, Instagram, Edwards, Security (finance), Transcatheter arterial chemoembolization, Mitral valve, Risk, Securities Exchange Act of 1934, Adrenal insufficiency, Twitter, LinkedIn, Securities Act of 1933, Stroke, Structural heart disease, Randomized controlled trial, Multimedia, University, TCT, Pharmaceutical industry, Medical imaging, Medical device, Patient, Facebook

The study confirms TEER as a safe and effective therapy in patients with degenerative mitral regurgitation (DMR).

Key Points: 
  • The study confirms TEER as a safe and effective therapy in patients with degenerative mitral regurgitation (DMR).
  • The PASCAL system further demonstrated significant and sustained MR 1+ with 83.7 percent of patients at MR 1+ at six months.
  • The CLASP IID trial is a prospective randomized controlled trial comparing the safety and effectiveness of the PASCAL system to the MitraClip system.
  • Edwards, Edwards Lifesciences, the stylized E logo, CLASP, Edwards PASCAL, Edwards PASCAL Precision, PASCAL, and PASCAL Precision are trademarks of Edwards Lifesciences Corporation.

EDWARDS PASCAL PRECISION TRANSCATHETER VALVE REPAIR SYSTEM RECEIVES FDA APPROVAL FOR DEGENERATIVE MITRAL REGURGITATION

Retrieved on: 
Thursday, September 15, 2022
YouTube, Securities Exchange Act of 1934, Adrenal insufficiency, PASCAL, Safety, Twitter, NYSE, Oregon Health & Science University, FDA, CLASP, Drug Quality and Security Act, TVT, Edwards Lifesciences, Division, LinkedIn, CE marking, News, Alfieri, Securities Act of 1933, U.S. Securities and Exchange Commission, Critical care, Patient, Forward-looking statement, History, Medical school, Instagram, Annual report, DMR, Leadership, TCT, Randomized controlled trial, Associate, Security (finance), Multimedia, Oregon Health and Science University Center for Women's Health, School, View, Mitral valve, Pharmaceutical industry, Medical device, Facebook

IRVINE, Calif., Sept. 15, 2022 /PRNewswire/ --Edwards Lifesciences Corporation (NYSE: EW), today announced the company's PASCAL Precision transcathetervalve repair system for transcatheter edge-to-edge repair (TEER) has received FDA approval for the treatment of patients with degenerative mitral regurgitation (DMR).

Key Points: 
  • IRVINE, Calif., Sept. 15, 2022 /PRNewswire/ --Edwards Lifesciences Corporation (NYSE: EW), today announced the company's PASCAL Precision transcathetervalve repair system for transcatheter edge-to-edge repair (TEER) has received FDA approval for the treatment of patients with degenerative mitral regurgitation (DMR).
  • With FDA approval of the PASCAL system, US clinicians now have an additional option for treating patients with severe mitral regurgitation."
  • Transcatheter Edge-to-Edge Repair (TEER) of the mitral valve isused in the treatment of mitral regurgitation.
  • Edwards, Edwards Lifesciences, the stylized E logo, CLASP, Edwards PASCAL, Edwards PASCAL Precision, PASCAL, and PASCAL Precision are trademarks of Edwards Lifesciences Corporation.

EDWARDS ANNOUNCES KEY EVENTS FOR EUROPCR 2022

Retrieved on: 
Monday, May 16, 2022
Use, U.S. Securities and Exchange Commission, Contraindication, European Association for Evolutionary Political Economy, Aortic stenosis, Patient, View, PASCAL, News, Multimedia, Association, Edwards, CE, Marketing, CLASP, AVR, Securities Act of 1933, Securities Exchange Act of 1934, Critical care, YouTube, Instagram, Forward-looking statement, Edwards Lifesciences, Safety, Sale, Prognosis, Security (finance), LinkedIn, Twitter, TVT, NYSE, Medical device, Annual report, Pharmaceutical industry, Facebook

PARIS, May 16, 2022 /PRNewswire/ --Edwards Lifesciences Corporation (NYSE: EW) announced key events for the company during EuroPCR 2022, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI).

Key Points: 
  • PARIS, May 16, 2022 /PRNewswire/ --Edwards Lifesciences Corporation (NYSE: EW) announced key events for the company during EuroPCR 2022, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI).
  • TriCLASP post-market study: 30-day outcomes On May 19, 30-day outcomes of the Edwards PASCAL transcatheter valve repair systemwill be presented.
  • The Edwards Cardioband System, and the Edwards PASCAL Systems are for professional use where CE marking is accepted.
  • Edwards, Edwards Lifesciences, the stylized E logo, Cardioband, CLASP, PARTNER, PASCAL and TriCLASP are trademarks of Edwards Lifesciences Corporation.

Iridex Announces First Quarter 2022 Financial Results

Retrieved on: 
Thursday, May 12, 2022
KOL, Company, Traction, U.S. Securities and Exchange Commission, Nasdaq, PASCAL, IRIX, Marketing, Securities Act of 1933, Glaucoma, SECURE Act of 2019, Sale, Diabetic retinopathy, Adoption, Ophthalmology, Growth, COVID, United, Security (finance), DME, CEO, Annual report, GLOBE, Pharmaceutical industry, Video game, Renewable energy, Topcon, Retina

MOUNTAIN VIEW, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX) today reported financial results for the first quarter ended April 2, 2022.

Key Points: 
  • MOUNTAIN VIEW, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX) today reported financial results for the first quarter ended April 2, 2022.
  • Revenue for the three months ended April 2, 2022 increased 12% to $13.4 million from $12.0 million during the same period of the prior year.
  • Retina product revenue improved in the first quarter to $7.3 million, an increase of 10% compared to the prior year period.
  • Operating expenses for the first quarter of 2022 increased 22% to $8.3 million compared to $6.8 million in the same period of the prior year.

Edwards Lifesciences Outlines Growth Strategy at Annual Investor Conference

Retrieved on: 
Wednesday, December 8, 2021
U.S. Securities and Exchange Commission, Edwards Lifesciences, Physician, Twitter, Company, Forward-looking statement, Securities Act of 1933, Oregon Health & Science University, YouTube, GAAP, Growth, Security (finance), PASCAL, Forecasting, Investor relations, Edwards, Safety, Food, View, News, Patient, Viewfinder, Securities Exchange Act of 1934, Critical care, Interventional cardiology, MD, TAVR, Multimedia, COVID-19, CLASP, Adoption, Patent, Instagram, Intellectual property, Public expenditure, LinkedIn, Regulation of tobacco by the U.S. Food and Drug Administration, Sale, Q&A, Investment, Webcast, Hospital, Pharmaceutical industry, Risk management

The Edwards Lifesciences 2021 investor conference can be accessed via live webcast at ir.edwards.com beginning at 8:30 a.m. Pacific Time today.

Key Points: 
  • The Edwards Lifesciences 2021 investor conference can be accessed via live webcast at ir.edwards.com beginning at 8:30 a.m. Pacific Time today.
  • The webcast will be archived on the "Investor Relations" section of the Edwards website at ir.edwards.com or www.edwards.com .
  • Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease and critical care monitoring.
  • Edwards, Edwards Lifesciences, the stylized E logo, Alterra, CLASP, Edwards SAPIEN, Edwards SAPIEN 3, Edwards SAPIEN X4, The EARLY TAVR trial, ENCIRCLE, EVOQUE, EVOQUE Eos, HemoSphere, INSPIRIS, INSPIRIS RESILIA, KONECT, KONECT RESILIA, MITRIS, MITRIS RESILIA, PASCAL, PASCAL Precision, SAPIEN M3, TRISCEND, and Viewfinder are trademarks of Edwards Lifesciences Corporation.